SARS-CoV-2与肝脏:慢性肝病中的临床与免疫学特征
本文综述慢性肝病(CLD)患者SARS-CoV-2感染的临床与免疫学特征。急性肝损伤在SARS-CoV-2感染中常见,可能由细胞因子、直接病毒感染或COVID-19药物毒性等多因素诱导。CLD患者感染后病程可能更重并促进失代偿,尤其肝硬化患者;其SARS-CoV-2特异性适应性免疫应答在自然感染和疫苗接种后均受损,但加强接种后至少部分改善。疫苗接种后罕见急性疫苗诱导性肝损伤和自身免疫样肝炎,但肝酶升高在类固醇治疗下可逆。
要点
- 急性肝损伤在SARS-CoV-2感染中常见,可能由细胞因子、直接病毒感染或药物毒性等多因素诱导。
- CLD患者感染SARS-CoV-2后病程可能更重并促进失代偿,尤其肝硬化患者。
- CLD患者自然感染和疫苗接种后SARS-CoV-2特异性适应性免疫应答受损,加强接种后至少部分改善。
核心结论
- CLD患者感染SARS-CoV-2后病程可能更严重并促进失代偿,尤其肝硬化患者。
- CLD患者自然感染和疫苗接种后SARS-CoV-2特异性适应性免疫应答受损,但加强接种后至少部分改善。
- 疫苗接种后罕见急性疫苗诱导性肝损伤和自身免疫样肝炎,肝酶升高在类固醇治疗下可逆。
研究设计与样本
- 本文为综述,总结CLD患者SARS-CoV-2感染的临床与免疫学特征。
主要发现
- 急性肝损伤在SARS-CoV-2感染中常见,可能由细胞因子、直接病毒感染或COVID-19药物毒性等多因素诱导。
- CLD患者感染SARS-CoV-2后病程可能更重并促进失代偿,尤其肝硬化患者。
- 与健康个体相比,CLD患者自然感染和疫苗接种后SARS-CoV-2特异性适应性免疫应答受损,但加强接种后至少部分改善。
- 疫苗接种后罕见急性疫苗诱导性肝损伤和自身免疫样肝炎,肝酶升高在类固醇治疗下可逆。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
SARS-CoV-2 infection may affect the liver in healthy individuals but also influences the course of COVID-19 in patients with chronic liver disease (CLD). As described in healthy individuals, a strong SARS-CoV-2-specific adaptive immune response is important for the outcome of COVID-19, however, knowledge on the adaptive immune response in CLD is limited.Here, we review the clinical and immunological features of SARS-CoV-2 infection in individuals with CLD. Acute liver injury occurs in many cases of SARS-CoV-2 infection and may be induced by multiple factors, such as cytokines, direct viral infection or toxic effects of COVID-19 drugs. In individuals with CLD, SARS-CoV-2 infection may have a more severe course and promote decompensation and particularly in patients with cirrhosis. Compared with healthy individuals, the SARS-CoV-2-specific adaptive immune responses is impaired in patients with CLD after both, natural infection and vaccination but improves at least partially after booster vaccination.Following SARS-CoV-2 vaccination, rare cases of acute vaccine-induced liver injury and the development of autoimmune-like hepatitis have been reported. However, the concomitant elevation of liver enzymes is reversible under steroid treatment.
引用
- Luxenburger H, Thimme R. SARS-CoV-2 and the liver: clinical and immunological features in chronic liver disease. Gut. 2023. PMID: 37316169. doi:10.1136/gutjnl-2023-329623
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。